文献速递浆细胞疾病

多发性骨髓瘤患者接种SARS CoV-2疫苗后中和抗体应答的决定因素

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
PubMed 文献 · J Clin Oncol · 2022-03-08

研究分析238例多发性骨髓瘤患者接种SARS CoV-2疫苗后的血清,检测抗 Spike 受体结合域(RBD)抗体及假病毒和活病毒中和能力。疫苗诱导的中和抗体可检出率仅54%,33%患者的抗RBD抗体缺乏可检测的中和能力;接种 mRNA1273(Moderna)者中和抗体诱导率显著高于接种 BNT162b2(Pfizer)者(67% 对 48%,P = .006)。

要点

  • 238例多发性骨髓瘤患者接种SARS CoV-2疫苗后,疫苗诱导中和抗体可检出率为54%。
  • 33%患者的疫苗诱导抗Spike RBD抗体缺乏可检测的中和能力,包括针对B1.617.2变异株。
  • 接种mRNA1273者中和抗体诱导率67%,显著高于接种BNT162b2者的48%(P = .006)。

核心结论

  • 部分多发性骨髓瘤患者疫苗诱导的抗体缺乏可检测的病毒中和活性。
  • 疫苗介导的中和抗体诱导受种族、疾病、疫苗和治疗特征影响。
  • 这些数据对免疫受损宿主中加强针疫苗的新兴应用有多方面意义。

研究设计与样本

  • 研究分析了238例接受SARS CoV-2疫苗接种的多发性骨髓瘤患者的血清。
  • 检测抗SARS CoV-2 Spike受体结合域(RBD)抗体和病毒核衣壳抗体,以判断疫苗血清学应答和病毒环境暴露。
  • 采用假病毒中和试验和活病毒中和试验,针对初始SARS CoV-2毒株和B1.617.2(Delta)变异株定量抗体中和病毒的能力。

主要发现

  • 疫苗诱导的中和抗体可检出率为54%,远低于既往未监测病毒中和的多发性骨髓瘤血清转阳研究中的估计值。
  • 33%患者的疫苗诱导抗Spike RBD抗体缺乏可检测的中和能力,包括针对B1.617.2变异株。
  • 接种mRNA1273(Moderna)疫苗者中和抗体诱导率67%,接种BNT162b2(Pfizer)疫苗者48%,前者显著高于后者(P = .006)。
  • 中和抗体的诱导受种族、疾病和治疗相关因素影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of COVID-19-related mortality and exhibit variable serologic response to the vaccine. The capacity of vaccine-induced antibodies in these patients to neutralize SARS CoV-2 or its variants is not known. METHODS: Sera from 238 patients with multiple myeloma (MM) undergoing SARS CoV-2 vaccination were analyzed. Antibodies against the SARS CoV-2 spike receptor-binding domain (RBD) and viral nucleocapsid were measured to detect serologic response to vaccine and environmental exposure to the virus. The capacity of antibodies to neutralize virus was quantified using pseudovirus neutralization assay and live virus neutralization against the initial SARS CoV-2 strain and the B1.617.2 (Delta) variant. RESULTS: Vaccine-induced nAbs are detectable at much lower rates (54%) than estimated in previous seroconversion studies in MM, which did not monitor viral neutralization. In 33% of patients, vaccine-induced antispike RBD antibodies lack detectable neutralizing capacity, including against the B1.617.2 variant. Induction of nAbs is affected by race, disease, and treatment-related factors. Patients receiving mRNA1273 vaccine (Moderna) achieved significantly greater induction of nAbs compared with those receiving BNT162b2 (Pfizer; 67% v 48%, P = .006). CONCLUSION: These data show that vaccine-induced antibodies in several patients with MM lack detectable virus-neutralizing activity. Vaccine-mediated induction of nAbs is affected by race, disease, vaccine, and treatment characteristics. These data have several implications for the emerging application of booster vaccines in immunocompromised hosts.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Nooka AK, Shanmugasundaram U, Cheedarla N, et al. Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. J Clin Oncol. 2022. PMID: 35259002. doi:10.1200/JCO.21.02257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。